Anti-CV2/CRMP5 Paraneoplastic Chorea Effectively Managed with Intravenous Amantadine

Ha, Jongmok; Na, Boo Suk; Ahn, Jong Hyeon; Kim, Minkyeong; Kim, Jae Woo; Lee, Jae Hyeok; Cho, Jin Whan; Kim, Ji Sun; Youn, Jinyoung

Background: Paraneoplastic chorea is typically a subacute progressive hyperkinetic movement disorder. The mainstay of treatment is managing the underlying neoplasm. However, the clinical course may be variable, and effective symptomatic management can precede the start of cancer treatment.

Case report: A 63-year-old man presented with insidious onset, slowly progressive generalized chorea for 1 year, later diagnosed as anti-CV2/CRMP5 autoantibody positive paraneoplastic chorea. His chorea was markedly improved with intravenous amantadine.

Discussion: In patients with anti-CV2/CRMP5 autoantibody-related chorea, sequential follow-up of brain magnetic resonance imaging reveals progression from active inflammation to atrophy. Our report highlights the efficacy of intravenous amantadine in paraneoplastic chorea.


  • thumnail for 701-Article Text-16421-1-10-20191010.pdf 701-Article Text-16421-1-10-20191010.pdf application/pdf 372 KB Download File

Also Published In

Tremor and Other Hyperkinetic Movements

More About This Work

Academic Units
Center for Parkinson's Disease and Other Movement Disorders
Published Here
January 15, 2020